COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes20/06/2017
-   
  Galapagos increases share capital through warrant exercises20/06/2017
-   
  Oriola Corporation starts repurchase of its own class B shares in connection with the company's incentive schemes20/06/2017
-   
  New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs20/06/2017
-   
  The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement20/06/2017
-   
  Holaira Announces Company Name Change to Nuvaira20/06/2017
-   
  The Jackson Laboratory et Crown Bioscience annoncent un accord mondial de recherche préclinique20/06/2017
-   
  Holaira annonce le changement de dénomination de la société pour devenir Nuvaira20/06/2017
-   
  Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC20/06/2017
-   
  Nokia launches portfolio of digital health products designed to inspire people to take control of their health20/06/2017
-   
  Galapagos' R&D Update 2017: rapidly advancing our product candidates20/06/2017
-   
  Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval20/06/2017
-   
  Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden20/06/2017
-   
  argenx receives second preclinical milestone payment in collaboration with LEO Pharma20/06/2017
-   
  NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS20/06/2017
-   
  NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS20/06/2017
-   
  Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients20/06/2017
-   
  Takeda et TiGenix annoncent que Swissmedic a accepté la demande d'évaluation relative au Cx106 pour le traitement des fistules périanales complexes chez les patients atteints de la maladie de Crohn.20/06/2017
-   
  Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma20/06/2017
Pages